Beyond the Headlines: Fisetin — Can We Really Clear Away the “Zombie” Cells of Aging?

A Bio Precision Aging feature | Reading time: 7–9 minutes

There is a strange idea at the heart of aging research: some of the cells in your body don't die when they should. Instead, they enter a kind of biological limbo.They stop dividing. They don't function normally. But they don't disappear, either. And perhaps more importantly, they can begin releasing a cocktail of inflammatory signals that affect the cells around them.

Researchers call these senescent cells. The popular press has given them a more memorable name: “zombie cells.” And this is where fisetin enters the story.

Fisetin is a naturally occurring flavonoid found in foods such as strawberries, apples, persimmons, cucumbers, onions and grapes. It has been studied for years as a plant compound with antioxidant and anti-inflammatory properties. Then something changed.

In 2018, researchers from the Mayo Clinic and Scripps Research Institute screened ten related flavonoids to see which might selectively eliminate senescent cells. Fisetin emerged as the most potent compound in the group. [1]

That finding helped move fisetin from an interesting nutritional compound into one of the more closely watched senolytics in geroscience—the emerging field focused on targeting the biological mechanisms of aging.

But here's where the story gets interesting.

Fisetin has produced some remarkable results in animals. Human evidence is beginning to emerge. But we are not yet at the point where anyone can honestly say that taking fisetin will make you live longer.

That distinction matters. Because the promise of senolytics is enormous. So is the temptation to get ahead of the science.

The “zombie cell” problem

Think about your body as a city. Cells are constantly being created, doing their jobs, becoming damaged and eventually being removed. It's an extraordinarily sophisticated recycling system.

But with age, some cells enter senescence. They essentially stop dividing but remain metabolically active. Worse, some begin releasing inflammatory molecules collectively known as the senescence-associated secretory phenotype, or SASP.

It's as if a damaged building has stopped operating but is still pumping smoke into the neighborhood.The problem isn't necessarily one senescent cell.The problem is accumulation. As senescent cells build up, their inflammatory signals may influence neighboring cells and contribute to changes associated with aging, including impaired tissue repair, metabolic dysfunction and other age-related pathology. [1,2]

This is one reason senescent cells have become such an important target in longevity research. Rather than simply treating the symptoms of aging, researchers are asking a more fundamental question:

What if we could remove some of the biological debris that helps drive aging in the first place?

That's the senolytic idea.

Fisetin's unusual appeal

Fisetin isn't the only compound being studied as a senolytic. But it has an intriguing combination of characteristics.

It is naturally occurring. It has a plausible biological mechanism. It demonstrated senolytic activity in laboratory research. And, most importantly, researchers found evidence that it could produce meaningful effects when administered relatively late in life. In the landmark 2018 mouse study, researchers screened ten flavonoids and identified fisetin as the most potent senolytic compound tested. They then gave fisetin to aged mice. The results were striking.

Late-life treatment reduced markers of cellular senescence, improved tissue homeostasis, reduced age-related pathology and extended both median and maximum lifespan in the animals. The researchers also found supporting effects in human adipose tissue explants. [1]

That is exactly the kind of result that gets the longevity world excited. But it's also exactly where we need to be careful.

A mouse is not a human.

A compound that extends lifespan in mice has not automatically been shown to extend human healthspan—or lifespan. The real question is whether the biology translates.

The problem hiding inside a capsule

There's another complication that isn't nearly as glamorous as “killing zombie cells.”

Fisetin doesn't have particularly good oral bioavailability.

In plain English, your body doesn't absorb much of the fisetin you swallow. The compound has low water solubility and undergoes substantial first-pass metabolism. That means a conventional fisetin capsule may produce much lower blood exposure than the doses used in experimental models. [5]

Researchers have therefore been experimenting with ways to improve delivery.

In a randomized, double-blind crossover study involving 15 healthy volunteers, researchers compared 1,000 mg of standard fisetin with a hydrogel-encapsulated formulation.

The difference was dramatic.

The hydrogel formulation produced approximately 26.9 times greater overall plasma exposure and more than 23 times higher peak plasma concentrations, with no adverse events reported in the study. [5]

That finding has an important implication for anyone interested in senolytics:

The dose printed on the bottle isn't necessarily the dose your body actually experiences.

Formulation may matter enormously.

Fisetin isn't supposed to be a daily vitamin

This is perhaps the most important concept to understand about senolytics.

Most supplements are designed around continuous exposure. You take something every morning because the idea is to maintain a relatively steady level in your system.

Senolytics are different.

The theory is more like a hit-and-run strategy. Instead of continuously suppressing a pathway, an intermittent dose may temporarily push vulnerable senescent cells toward apoptosis—the biological process of programmed cell death—while leaving healthier cells relatively less affected.

In the animal studies, acute or intermittent fisetin treatment was sufficient to reduce

senescence markers across multiple tissues. [1]

That is why the idea of taking fisetin every single day indefinitely doesn't necessarily follow from the science. The objective isn't to keep fisetin circulating forever.

The objective, theoretically, is to periodically remove a biological population that shouldn't be there in the first place.

How might fisetin actually work?

The biology is complicated, but four pieces of the puzzle are particularly interesting.

First, fisetin appears to interfere with some of the survival mechanisms that senescent cells use to resist programmed cell death. Pathways involving PI3K/AKT and members of the BCL-2 family are among those implicated. [1]

Second, fisetin may reduce the inflammatory signals released by senescent cells. These include molecules such as IL-6, IL-8, MMP-7, MMP-9 and CRP. [7]

Third, as a flavonoid, fisetin also interacts with oxidative stress pathways and can activate Nrf2-related antioxidant responses. [1]

And fourth, there is evidence from human research that fisetin can influence matrix metalloproteinases and inflammatory markers. In one ischemic stroke study, adjunctive fisetin was associated with reductions in MMP-2, MMP-9 and CRP. [6]

Put together, these findings suggest that fisetin may be doing more than one thing.

But there's a crucial distinction:

Mechanistic activity is not the same as clinical benefit.

A molecule can change an inflammatory marker without changing how long a person lives.

That's why human trials matter.

The human evidence is where the story gets real

One of the biggest developments in senolytic research has been the transition from animal experiments into human clinical trials.

The Translational Geroscience Network has helped move senolytics into early-stage human research, including trials examining fisetin in conditions associated with aging and cellular senescence. [2]

One example is the COVFIS-HOME trial, an NIH-funded multicenter placebo-controlled study examining fisetin in COVID-19-positive residents of skilled nursing facilities. The rationale was based partly on the overlap between senescence-associated inflammatory signaling and the inflammatory response associated with severe COVID-19. [3]

Another is the STOP-Sepsis trial.

This multicenter randomized, double-blind Phase 2 study enrolled adults over 65 with sepsis and compared placebo with single- and two-dose fisetin regimens of 20 mg/kg. Researchers are examining outcomes including organ failure scores, senescent CD3+ cells and 28-day mortality. [4]

This is important because it moves the discussion from:“Fisetin works in mice.”to:

“Does targeting senescent cells actually improve outcomes in humans?”

That's the question we ultimately care about.

There have been encouraging signals but also a reality check

Not every fisetin study has produced a positive result. In a study involving people with Gulf War Illness, fisetin did not significantly reduce symptom severity at either dose tested. [8]

That's not a footnote to ignore. It's actually one of the more valuable pieces of evidence in the entire fisetin story.

Why?

Because it reminds us that a compound can have a compelling mechanism without producing meaningful benefits in every disease. Senescence isn't one disease. Inflammation isn't one disease. And fisetin isn't going to be a universal biological reset button.

The Gulf War Illness result suggests that any benefits from fisetin may be indication-specific, rather than simply a consequence of taking an anti-inflammatory compound. [8]

That's precisely why precision longevity medicine is so important.

Where might fisetin fit into precision longevity?

The most interesting application of fisetin may not be: “Everyone over 50 should take fisetin.” That would be getting far ahead of the evidence.

A more rational question is: Who might have the most to gain from targeting senescent cells?

The source evidence suggests the compound is most appropriately considered in people with signs of an inflammatory aging phenotype or elevated metabolic risk, rather than as a universal longevity supplement.

Potentially relevant signals include elevated hs-CRP, IL-6 or IL-8, features of metabolic syndrome and certain age-associated conditions such as osteoarthritis. [6,7]

But there is a major limitation here.

We currently don't have a universally accepted clinical test that tells you:

“Your senescent cell burden is X% higher than it should be, therefore you should take fisetin.” That test doesn't exist yet.

Researchers are still working on reliable biomarkers of biological senescence.

So for now, fisetin is better viewed as a research-driven adjunct within a broader longevity strategy, rather than a routine supplement for everyone.

What about dosing?

This is where online longevity discussions can become particularly confusing.

The evidence base contains several very different dosing approaches, and they should not be treated as interchangeable.

The STOP-Sepsis trial uses an intermittent regimen of 20 mg/kg per day for two consecutive days, rather than continuous daily administration. For an 80-kg adult, that works out to approximately 1,500–1,600 mg per day for those two days. [4] That's a research protocol—not proof that everyone should copy it.

There is also a lower-dose approach that has been studied in a colorectal cancer population: 100 mg per day for seven weeks was associated with reductions in inflammatory markers including IL-8 and hs-CRP. Importantly, that study was examining inflammatory effects, not proving a senolytic effect. [7]

Those are two very different objectives. One is attempting to exploit a senolytic strategy.The other is examining changes in inflammatory markers.That distinction is easy to lose when supplement protocols get reduced to a number on a label.

The formulation question may be just as important as the dose

Remember that pharmacokinetic study?

The hydrogel formulation produced roughly 23- to 27-fold greater systemic exposure than unformulated fisetin. [5]

That means two people could swallow the same nominal dose and potentially experience dramatically different systemic exposure depending on the formulation.

This is one reason bioavailability-enhanced formulations—including hydrogel, liposomal or phospholipid-based approaches—are being explored.

It also means that simply taking more conventional fisetin isn't necessarily the smartest strategy.

More milligrams do not automatically equal more biological effect.

The goal is meaningful exposure, not an impressive number printed on a supplement bottle.

Safety: promising, but don't confuse “well tolerated” with “proven safe forever”

The human studies reviewed in the source material generally report a favorable short-term safety profile.

No adverse events were reported following single doses up to 1,000 mg in the pharmacokinetic study, and no significant safety signals were reported in the colorectal cancer, Gulf War Illness or stroke adjunct studies described here. [5,6,7,8]

But the higher intermittent doses being explored in older, medically vulnerable populations are still being studied. The STOP-Sepsis and COVFIS-HOME trials are particularly important because they will provide additional information about safety in populations that are more vulnerable to adverse events. [3,4]

There are also situations where fisetin deserves particular caution.

People taking anticoagulant or antiplatelet medications should discuss fisetin with their physician because flavonoids can have antiplatelet effects.

Anyone undergoing active chemotherapy should use fisetin only under the direction of the oncology team.

There are insufficient human safety data to recommend fisetin during pregnancy or breastfeeding, and it has not been adequately studied in children.

People taking medications with narrow therapeutic windows that are metabolized through pathways involving CYP3A4 or CYP2C9 should also have their medication profile reviewed before considering fisetin. [5]

The longevity question nobody should skip

Here's where fisetin becomes genuinely fascinating.

The idea of senolytics challenges the traditional approach to aging medicine.

Instead of asking:

“What medication treats this disease?”

researchers are asking:

“What biological process is contributing to several diseases at once and can we intervene upstream?”

If senescent cells contribute to multiple aspects of aging, then selectively removing them could theoretically have effects across several systems. That's the promise. But we're still testing that promise in humans.

At this point, there is no completed human trial demonstrating that fisetin extends human healthspan or lifespan.

There is also no validated clinical senescence-biomarker panel that can definitively demonstrate that a person has successfully “cleared” their senescent cells after taking fisetin.Those are not minor details.They are the boundary between promising longevity science and marketing.

So, is fisetin ready for prime time?

Not quite. But it's getting interesting.

Fisetin has an unusually compelling preclinical story. It was identified through systematic screening as a potent senolytic, reduced senescence markers in animal models, improved age-related pathology and extended lifespan in aged mice. [1]

Human research has demonstrated that fisetin can be delivered safely in early studies and that formulation can dramatically change systemic exposure. [5]

There are also early human signals involving inflammatory markers and clinical outcomes in specific settings. [6,7]

But we don't yet have the result that would change the conversation completely:

A well-controlled human trial showing that eliminating senescent cells with fisetin meaningfully improves healthspan.

That's the result we're waiting for and perhaps that's exactly where the excitement should be. Because unlike many longevity ideas that remain speculative, senolytics have moved far enough down the research pipeline that we're beginning to test the central hypothesis in humans.

Beyond the headline

The headline might say: “Fisetin kills zombie cells and could slow aging.”

That's catchy. The scientific reality is much more interesting.

Fisetin is a promising senolytic compound with a compelling mechanism, impressive results in aged mice, demonstrated human pharmacokinetic activity and early clinical signals.

But promising isn't proven.

The most rational approach today is not to treat fisetin as a miracle longevity supplement. It's to view it as an emerging tool that may eventually become part of precision longevity medicine—particularly if researchers can determine which people have the greatest senescent-cell burden, which formulations deliver meaningful exposure and which clinical outcomes actually improve when those cells are targeted.

That is the real opportunity.

If the senolytic hypothesis proves correct in humans, we may eventually have a fundamentally different way of thinking about aging—not simply managing the diseases that accumulate with age, but periodically removing some of the cellular damage that helps create them.

That's a much bigger idea than a supplement.

And it's one worth watching closely.

References

[1] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. PMID: 30279143.

[2] Wissler Gerdes EO, Misra A, Netto JME, Tchkonia T, Kirkland JL. Strategies for late phase preclinical and early clinical trials of senolytics. Mech Ageing Dev. 2021;200:111591. PMID: 34699859.

[3] Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. J Am Geriatr Soc. 2021;69(11):3023-3033. PMID: 34375437.

[4] Silva M, Wacker DA, Driver BE, et al. Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients. Trials. 2024;25(1):698. PMID: 39434114.

[5] Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals. J Nutr Sci. 2022;11:e74. PMID: 36304817.

[6] Wang L, Cao D, Wu H, Jia H, Yang C, Zhang L. Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator. Clin Appl Thromb Hemost. 2019;25:1076029619871359. PMID: 31434498.

[7] Farsad-Naeimi A, Alizadeh M, Esfahani A, Darvish Aminabad E. Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food Funct. 2018;9(4):2025-2031. PMID: 29541713.

[8] Hodgin KS, Donovan EK, Kekes-Szabo S, et al. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol, Luteolin, and Fisetin. Int J Environ Res Public Health.2021;18(5):2483. PMID: 33802381.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented is intended to support informed conversations with your licensed healthcare provider. Consult a qualified physician before initiating any new health protocol, supplement regimen, or medical intervention. Individual results vary.